The generation of induced pluripotent stem (iPS) cells by controlled delivery of reprogramming factors enables the derivation of pluripotent cells from a variety of somatic cell types. Patient-tailored iPS cells remove the major roadblock of immune rejection for clinical applications associated with the use of human embryonic stem (hES) cells. Beside therapeutic issues, iPS cell technology opens the door for broader research on human pluripotent cells because ethical limitations are lifted with iPS cells compared to hES cells. Scientists are now able to generate iPS cells for disease modelling and use them in basic research of physiological and pathophysiological models. In this concise review, we discuss the state of the art in the field of iPS cell induction by cell fusion or defined factors. Techniques to derive pluripotent cells from somatic sources are introduced and discussed, as well as some biological factors that influence the generation of iPS cells. We compare ES and iPS cells to answer the question whether these cells are identical, and we finish with an outlook on clinical research with iPS cells with a focus on cardiovascular medicine.
Introduction
The generation of induced pluripotent stem (iPS) cells by reprogramming of somatic cells is one of the most fascinating developments in the history of life science. When Yamanaka and his team in 2006 described that the expression of a set of only four genes (Klf4, Sox2, Oct4 and c-Myc) transformed somatic cells back into a pluripotent-like state, the scientific community remained sceptical [1] . In cell culture, these first iPS cells behaved like fully pluripotent embryonic stem (ES) cells, but it quickly became clear that they lacked the potential to generate transgenic animals [1] . One year later, however, the laboratory of Rudolf Jaenisch showed that murine iPS cells genetically selected for pluripotency resulted in chimera when injected into murine blastocysts [2] . It can be speculated that the Japanese group's initial failure to generate fully reprogrammed cells might be due to incomplete reprogramming because these researchers did not wait long enough before cells were harvested for fur- 106 ther analysis. Eventually, these findings initiated a true revolution in the field of stem cell science and especially excited scientists who focus on therapeutic aspects of stem cells. Soon after the discovery of murine iPS cells, Yamanaka's group announced the successful generation of human iPS cells by the same set of genes. Thomson and co-workers also succeeded in this effort, but with an alternative gene combination comprised of Oct4, Sox2, Nanog and Lin28 [3, 4] .
While the potential use of human ES cells for therapeutic applications comes with immunological problems similar to those encountered during organ transplantation, reprogramming of somatic cells promises to provide custom-made pluripotent cells from individual patients (for a review on immunological properties of ES cells, see [5] ). In addition, whether intended for clinical or basic research, human ES cells are the subject of intense ethical debates. The use of early human embryos as a source for derivation of ES cell lines is difficult to accept in varions cultural backgrounds and, therefore, research on human ES cells is heavily restricted in many countries. Moreover, research even on established human ES cell lines is immensely complicated by regulations. From this point of view, the use of iPS cells opens new chances for research on human pluripotent cells and allows, for example, investigations into earliest cell differentiation processes. Currently, the comparison of ES and iPS cells and their derivatives is the topic of many studies and is intensively discussed in the community. Embryonic stem cells are obviously the "gold standard" for pluripotent cells and remain indispensable to identify and understand differences between ES and iPS cells [6] .
In this review, we first summarize the development of current reprogramming techniques and the biological background. We then focus on current knowledge gained from ES and iPS cell comparisons and, finally, discuss aspects of clinical applications of iPS cells for physiology and pharmaceutical development. Pioneer experiments using frog oocytes that provided first evidence for reprogramming, as well as aspects of nuclear cloning in mammals, are out of the scope of this review and were concisely discussed by Gurdon and Melton [7] .
Reprogramming of somatic nuclei to a pluripotent state
The possibility to completely reverse the differentiation pattern of a fully differentiated cell to a pluripotent ground state has been the subject of many studies.
Pioneers in cell biology have dealt with the question whether cells may alter their genome or loose genetic information during specification, or whether they acquire additional heritable information during their lifetime, as, for example, postulated by Brooks [8] . Today, it is common knowledge that most cells in our body keep the genetic information during pre-and postnatal development, and during the whole lifetime of an organism. This is an important fact and a prerequisite for the possible transformation of any cell into any other cell type of the same species.
Somatic cell nuclear transfer was one of the first methods to reprogram terminally differentiated cells. The nucleus of a completely differentiated cell can be transferred to an enucleated unfertilized egg in order to generate reprogrammed cells. These cells have the ability to produce live offspring, thus revealing the potency of these cells to differentiate into different cell types [9] . Subsequent to experiments by Tada and colleagues in which embryonic germ cells were fused with thymocytes, it was shown that the DNA methylation pattern of the thymic lymphocytes nuclei was largely erased in the fusion hybrids [10] . Furthermore, hybrid cells that were generated by fusion appeared to behave like pluripotent cells and contributed to a variety of different tissues in chimeric embryos. Even though these early results of reprogramming somatic nuclei to pluripotent states indicated the exciting possibility to revert differentiated cells towards multi-or even pluripotency, it took almost a decade for these experiments to enter the limelight of cell biology. Already in 2001, the reactivation of the pluripotency marker Oct4 from a somatic chromosome was shown by fusion of thymocytes with ES cells [11] . In addition, the inactive X chromosome from the female somatic fusion partner showed signs of reactivation [11] . The latter was already demonstrated by Yoshida and colleagues who succeeded to transfer inactive human X chromosomes by microcell fusion into murine embryonic carcinoma cells resulting in a reactivation of the silent X chromosome [12] .One year later, it was shown that the co-culture of ES cells and neural stem cells leads to spontaneous fusion of both cell types [13] . The resulting fusion hybrids reactived silenced ES-specific genes on somatic chromosomes, indicating reprogramming of somatic chromatin [13] . The fusion hybrids formed pluripotent colonies that contributed to chimeric embryos when transplanted into blastocysts. Experiments with cytoplasts and karyoplasts of ES cells that were fused to neuronal stem cells also demonstrated that the ability to activate Oct4 from a somatic locus is restricted to the ES cell nucleus [14] .
In 2005, the fusion technique was successfully applied to reprogram human fibroblasts by human embryonic stem cells, resulting in pluripotent hybrid cells with a morphology resembling human ES cells . The strategy to select fusion hybrids was based on the use of human ES cells that were resistant against one antibiotic while fibroblasts were resistant against a second one. Addition of polyethyleneglycole then led to formation of hybrid cells that could survive in the presence of both antibiotics. The resulting colonies were tetraploid and exhibited features of embryonic cells. Obviously, a major disadvantage of this approach is that it leads to tetraploid products. Sophisticated methods were subsequently developed to eliminate single chromosomes, but it turned out that removal of the whole chromosome set coming from the embryonic stem cell is not possible [16] . Even though scientist found that chromosomes were lost during prolonged culture of hybrids, these chromosomes were initially contributed by the somatic fusion partner [17] [18] [19] .
In conclusion, use of the fusion technique to generate patient-tailored pluripotent cells from a tissue biopsy appears rather limited because of contaminating genetic information from the ES cell fusion partner. With the development of iPS technologies cell fusion seems to be out of date. We will see, however, that the fusion approach could still be of interest to address the basics of cell reprogramming.
Physiology of reprogramming and roadblocks to be eliminated
Apart from the genetic information stored in the nucleotide sequence, the genome packed in chromatin bears an epigenetic as well as a proteomic and epiproteomic profile of nucleosomes. These profiles provide important information for a cell's identity and expression of its individual genes [20] .
The methylation pattern of DNA is among the modifications of great importance for the transcriptional regulation of a cell. Methylation of distinct CpG islets accounts for silencing or activation of many genes, and has global impact on cell identity. Methylation of promoter regions results in silencing of transcription in most, but not all cases. In addition, modifications of core histones regulate the transcriptional activity, which will be discussed below in more detail.
During development the methylation pattern of DNA undergoes major changes. In gametes and early stages of development the degree of methylation is low and the male nucleus undergoes further rapid demethylation after fertilization whereas the chromatin of the oocyte, which displays fewer methylation than the sperm, is more refractory to demethylation and looses the methylation probably in a passive process during cleavage [21, 22] . In the subsequent blastocyst stage, DNA of inner cell mass cells is hypomethylated and undergoes de novo methylation after implantation of the embryo [22, 23] . Hence, ES cells derived from pre-implantation blastocysts exhibit a very low level of genomic DNA methylation. Reprogramming of a differentiated cell must therefore involve demethylation of methylated genes. Alternatively, in can be hypothesised that an exchange of methylated cytosines for non-methylated cytosines might occur as demonstrated in certain plants (for a review see [24] ). Since methyl groups represent covalent genome modifications, a cell would require an enzymatic activity to remove them. No consensus mammalian demethylase enzyme has been identified so far, but its presence is being discussed [25, 26] .
Reactivation of pluripotency associated genes like Oct4 and Nanog are critically dependent on demethylation of the respective loci [27, 28] . To study the course of reprogramming and to identify factors involved in demethylation, fusions of ES cells and somatic cells are performed since they gain higher reprogramming efficiencies in shorter time periods compared to reprogramming with defined factors. In this context, experiments with heterospecies fusions have one advantage above fusions within one species: The expression of genes can be assayed with species-specific PCR primers for the somatic and the ES cell partner after fusion. Bhutani and colleagues made use of this and studied the course of reprogramming after fusion of human fibroblasts with murine ES cells. It was found that the activation of the human Nanog and Oct4 starts as early as one day after fusion. In comparison, the activation of the respective pluripotency markers during iPS cell generation takes approximately 2 weeks. More strikingly, the fused cells showed specific demethylation of Nanog and Oct4 loci in the absence of cell proliferation. This finding clearly indicates that demethylation is an active process and does not result from DNA replication. Interestingly, knock down of the AID gene, which is known to be involved in demethylation processes in mammalian germ cells, resulted in a failure of the cell hybrids to demethylate the human Oct4 and Nanog loci. This, in turn, resulted in a failure to upregulate these pluripotency factors, thus indicating a pivotal role for AID in the demethylation proc-ess during somatic reprogramming [29, 30] .
Besides the epigenetic methylation state of genomic DNA, structural variations of chromatin influence transcriptional activities and lead to transcriptional active regions called euchromatin and regions with lower activity, the heterochromatin. DNA is wrapped around a core of histone proteins and these nucleosomal core particles are linked by histone H1. DNA binding properties of histone proteins alter the strength of DNA-histone association. Furthermore, additional factors like polycomb proteins are involved in global regulation of transcription. Finally, matrix-attached regions within the chromatin result in silencing of local chromatin regions.
In ES cells, most of the chromatin is found in an "open state" with the genomic DNA arranged in transcriptional active euchromatin (for review see [31, 32] ). Chromatin binding and modelling factors like Chd1 and HMGA2 are supposed to promote this open chromatin state, but the exact mechanisms of their action remains to be elucidated [33, 34] . The DNA association of histone proteins has been described as hyperdynamic in ES cells, and even though DNA is bound by histones most of the time, there is a very fast exchange between DNAassociated and the pool of free, diffusible histone proteins [32] . The open chromatin of ES cells is one key feature of these pluripotent cells, and the regulation of different chromatin states has been the subject of recent research activities. The process of reprogramming a somatic nucleus must, therefore, also involve the transition of silent parts of the somatic chromatin into more active states found in ES cells.
The interaction between DNA and core histones is regulated by histone modifications. Histone proteins are modified by acetylation, methylation and phosphorylation (for Review see [35] ). Acetylation of core histones reduces their affinity to DNA because it adds negative charges [36] . When Kimura and colleagues studied the effect of ES cell fusion to somatic nuclei, they found the reprogramming process of the nucleus associated with hyperacetylation of core histones H3 and H4 [37] . In addition, di-and trimethylation of the fourth lysine residue of histone H3 (H3K4) was not restricted to activated genes like Oct4, but was extended to silent genes, indicating that a change in histone modifications contributes to the global transition towards a transcription activation-permissive state, rather than regulation of individual genes.
This knowledge has facilitated the identification of inhibitors of histone deacetylating enzymes which are able to increase the efficiency of reprogramming. The transition from somatic to pluripotent cells requires major changes in chromatin structure, and the adaptation of histone modifications is probably one important factor in this process. Interestingly, it was found that treatmenent of neurosphere cells with trichostatin A and 5-Aza-2´-Deoxycytidine directly increases the expression of the pluripotency genes including Nanog, Oct4, Klf 4 and Dppa 2,3,4 and 5 [38] . These agents affect DNA methylation and histone acetylation. Valproic acid (VPA), a substance that loosens the binding of DNA to the core histones by inhibiting histone deacetylases and therefore increasing the level of acetylation, was found to increase Nanog expression when added to HELA cells (Pfannkuche K, unpublished results) .
The efficiency of reprogramming by delivery of the so-called "Yamanaka factors" is low. In their first report describing reprogramming of adult human fibroblasts by lentiviral introduction of Oct4, Klf4, Sox2 and c-Myc, Takahashi and colleagues reported generation of 10 hES like colonies per 50.000 fibroblasts transduced [3] . These rates could be increased up to 100-fold by the inclusion of VPA [39] . In addition, other cell types like keratinocytes were found to be less refractory to reprogramming than fibroblasts. Still, the efficiency of reprogramming remains quite low. In comparison, the efficiency of reprogramming by fusion of ES cells and somatic cells and the formation of a tetraploid fusion product reaches 70 percent in fusion hybrids, as estimated by Bhutani and colleagues [29] . From these experiments, it can be expected that cell fusion might still be of importance to analyse the basic mechanisms of reprogramming and the factors that are involved to make this an efficient process [29] .
The low efficiency of reprogramming of somatic cells by transduced reprogramming factors can lead to the speculation that small subpopulations within the primary cell preparations, potentially progenitor cells, are the target of the reprogramming process. A recent study of Byrne and colleagues supports this assumption by identification of a subpopulation of cells within dermal human fibroblasts that express the stage specific embryonic antigen 3 (SSEA3) and shows an increased expression of Nanog [40] . When used for reprogramming, the SSEA3 positive subpopulation yields elevated numbers of reprogrammed cells whereas the SSEA3 negative fraction failed to reprogram. In the contrary, Hanna and colleagues concluded that reprogramming is a stochastic process that does not specifically target small subpopulations, but occurs with different temporal delay [41] . To analyse the time course of reprogramming, a second generation reprogramming approach was utilized. In this approach mice that bear a doxycyclin-inducible cassette expressing all four "Yamanaka factors" were used for reprogramming. Premature B-lymphocytes from these mice can be grown clonally. When induced with doxycyclin, these pre-B-cells undergo reprogramming at different time points that seem to follow a linear relation. Onset of reprogramming as measured by activation of endogenous Nanog-expression was observed after 2 weeks in a small percentage of the cells. During further induction of the reprogramming factors more than 90% of all Pre-B cells indicated Nanog reactivation within 18 weeks. This process is subject to acceleration by different factors. While addition of Nanog accelerates the reprogramming beyond an increase in cell proliferation rate, the kinetics of Lin28 expression in reprogramming turned out to be directly correlated to shortening in cell cycle, thus pointing to the conclusion that Nanog but not Lin28 enhances reprogramming via direct actions. The latter holds true also for a p53 knock-down, which was reported to increase reprogramming efficiency [42, 43] .
Generation of iPS without viral integration
Use of retroviral vectors in the first generation of iPS cells allowed high efficiencies of transduction for induction of pluripotency in mouse embryonic fibroblasts. Later studies demonstrated the use of lentiviruses, which gave superior transduction efficiencies due to their ability to transfect non dividing cells. Maherali and colleagues developed doxycycline-inducible iPS cell lines, providing even higher iPS efficiencies with lentiviral vectors. Controllable factor expression overcomes problems related to inefficient silencing and reactivation of retroviruses and lentiviruses. On the other hand this system acts as a "dynamics tool" for gene expression analysis of different factors during iPS development and differentiation [44] .
During the culture of established iPS cells, lentiviral expression vectors are gradually silenced. This enables subsequent in vitro differentiation of iPS cell lines or blastocyste-transfer and formation of chimaeras with iPS cell-derived tissues. However, it turned out that animals generated by blastocyst injection of iPS cells tended to develop tumors [45] and it was speculated that the use of the oncogenic factor c-Myc as reprogramming factor equipped the cells with a substantial tumorigenic potential. We will discuss this topic below in more detail.
There are other reasons to evolve strategies for lentivirus-free iPS cell generation. One is that the introduction of foreign DNA that integrates itself at random positions in the genome bears a risk to influence cell physiology in an unpredictable manner via insertional mutagenesis. The transgene might destroy reading frames of genes or influences gene regulation. Maybe even more important is a possibility that silencing of lentiviral transgenes is incomplete in iPS cells leading to reactivation of lentiviral vectors [2] . It has been described that basal expression of lentiviral reprogrammings factors is found even in fully reprogrammed cells, and it was postulated that the level of expression of exogenous pluripotency factors indicates the stability of iPS cell lines, with the highest stabilities of lines observed when residual expression of reprogramming factors is lowest [46, 47] . During our own studies on the purification of spontaneously differentiating murine iPS cultures, we found a difference in the expression of viral Oct4 by three orders of magnitude between spontaneously differentiating iPS and stable subclones of the same origin, with still basal expression levels in high quality iPS [47] . From several studies, it is known that altered levels of pluripotency factors influence the fate of pluripotent cells. Overexpression of Oct4 seems to direct ES cells towards an endodermal fate [48, 49] . More strikingly, elevated levels of Sox2 can alter the whole network of pluripotency factors and abolish maintenance of pluripotency [50, 51] .
To overcome these limitations, different approaches have been explored to eliminate reprogramming factors or to prevent integration of foreign transgenes. The best strategy for generation of iPS cells for therapeutic issues might be to employ techniques that are able to reprogram somatic cells without the use of any type of DNA. One possibility to achieve this goal is the use of cell-permeable transcription factors. The short basic TAT domain derived from HIV is able to transduce proteins [52] . Even though protein transduction is rather inefficient and relatively high protein concentrations are needed, several applications achieve protein delivery in virtually 100% of fibroblast cells [53] . The application of cell permeable proteins for direct reprogramming has been shown with human newborn fibroblasts, but, again, the efficiency of reprogramming appears low [54] . The protocol described by Kim and colleagues includes incubation with the cell permeable factors for 42 days with six passage steps during incubation. Potentially reprogrammed cells could be isolated after 56 days and were identified as newly generated pluripotent stem cells. Even though the efficiency appears low, this study demonstrated for the first time that cell-permeable proteins can reprogram somatic cells. The clear advantage of this strategy is that no for- eign DNA has to be introduced. However, the long incubation time of 6 weeks in the presence of recombinant reprogramming factors in culture media, might be difficult in standard laboratory settings and other undesired effects might occur. A critical evaluation of genome integrity of the respective iPS cells will therefore be important. Another aspect requiring attention is the fact that no adult cell but newborn fibroblasts were reprogrammed, and, furthermore, that the cells used in the study bear karyotypic abnormalities. This might have influenced the outcome of the experiment in an unpredictable way. Taken together, the application of cell-permeable reprogramming factors is a very promising approach that certainly justifies further investigation to achieve efficient, less timeconsuming reprogramming of cells from adult donors. Recent results suggest that a substantial amount of cellpermeable reprogramming factors is trapped in endosomes after cell uptake and might therefore be unavailable for reprogramming [55] . Further optimisation of the protein transduction technique might help to overcome this problem. Another possibility to perform reprogramming without use of foreign DNA is introduction of RNA that can be transfected into cells. Transport of synthetic mRNAs to the nucleus is not necessary and, therefore, the transfection efficiency to deliver mRNA to the cytoplasm might be high. However, the stability of RNA is probably limiting the reprogramming efficiency and the actual amount of protein translated may require several rounds of transfection to achieve reprogramming.
A further strategy to induce pluripotency without the generation of stably transfected cells is the use of nonintegrating viruses. Adenoviral vectors were designed to express reprogramming factors and transport the coding sequence transiently into the target cells. In a first report it was demonstrated that adenoviral reprogrammed murine fibroblasts show demethylation indicative of reprogrammed cells, express pluripotency factors, and contribute to multiple tissue including the germ layer in chimeric mice [56] . Application of the adenoviral approach on fetal human fibroblasts resulted in the generation of stable human iPS cells without viral integration. The human iPS cells form teratomas in vivo, which is the most stringent assay applicable to test their pluripotency [57] . These reports demonstrate a potential use for adenoviral vectors to generate iPS cells free of foreign integrated DNA, but it, too, suffers from efficiencies as low as 0,0002%. In addition, data of reprogrammed adult human somatic cells is lacking and it is uncertain if the technique in its current form can reprogram fully differentiated cells. The use of fetal tissue is not widely applicable and does not prove the feasibility of this technique to perform efficient reprogramming of adult somatic cells. Adenoviral vectors might enhance the production of virus-free iPS cells with the improvement of current protocols, but the use of viruses that are DNA-based still bears a residual risk of integration into the host genome. This might be overcome with an RNA-based virus to generate safe iPS cells without application of DNA based vectors. The use of Sendai-Virus (SeV) yielded pluripotent iPS cells when fetal somatic cells were infected with viral particles [58] . The SeV is able to maintain its RNA genome inside the cytoplasm and bears no risk of DNA integration into the cellular genome. Removal of SeV after reprogramming is based on the spontaneous loss of SeV from a subset of cells during prolonged culture. Even though surface antigen based negative selection of virus-free cells is possible, the incidence of viral free cells was reported to appear sometimes as late as passage 30 and, furthermore, reprogramming of adult cells appears inefficient. These limitations might prevent broad application of the adenoviral as well as the SeV based techniques. However, improvements in reprogramming efficiency by small molecules and the use of "easy-to-reprogram" cells, like neural progenitors, might enhance the efficiency substantially, especially for adenoviral-based reprogramming.
A more feasible approach for daily laboratory use is the virus free reprogramming with vectors that contain Oct4, Klf4, c-myc and Sox2 on a single plasmid that can be stably transfected into somatic cells for reprogramming. The plasmid expressed a single mRNA that codes for all four reprogramming factors and the red-fluorescent protein (RFP) [59] . The coding sequences of the reprogramming factors are separated by self-cleaving sites that mediate the cleavage of a hollow-protein into active reprogramming factors. The RFP coding sequence, which is linked to the reprogramming factor sequences by an internal ribosome entry site, serves as a positive marker for transfection and generation of stable clones. Cells with stable integration of the whole vector are labelled by their expression of RFP and are resistant against geneticin allowing antibiotics-based selection of stable transfectants. Transgenic cell lines are undergoing reprogramming as measured by colony morphology change within one week and onset of alkaline phosphatase expression after 9 days. Colonies were collected 20-30 days after transfection. Subsequent removal of the whole expression cassette for reprogramming factors, including RFP, is achieved with Cre recombinase. The Cre recombinase performs recombination between loxP sites flanking the expression cassette. Delivery of Cre is possible either by transfection with Cre-expressing plasmids or by high efficient Cre protein transduction using cell-permeable Cre proteins [53] . A drawback of this method is that a segment of the backbone of the reprogramming plasmid is left behind in the genome even after Cre-mediated excision. However, stable transfection is a routine tool in cell biology and it is unlikely that the residual backbone of the plasmid expressing the geneticin resistance will lead to alterations of cell physiology in the vast majority of experimental settings. Altogether this seems to be a robust strategy to reprogram somatic cells for use in basic research without the employment of viral techniques, and with a strong advantage of removing reprogramming factors after successful generation of iPS cells.
Another powerful tool, not only for basic research, is the application of transposon-based systems. The application of the piggy-BAC transposon allows delivery of reprogramming factors into cells of different organisms and stable integration of the reprogramming genes into the genome by action of the transposase enzyme. The transposase enzyme, which is expressed from a transiently transfected plasmid, catalysed the integration of the reprogramming factors. Similar to the single plasmid strategy describe above, all reprogramming factors are coded on a single vector [60] . The whole cassette is flanked by inverted terminal repeats, which mediate insertion into the genome by the host-factor independent activity of a transposase. A strong advantage of the system is not only the higher efficiency to deliver reprogramming factors that makes it superior to the plasmid approach discussed before, but also the possibility to remove the transgene by repeated transient delivery of transposase. Under optimal conditions, traceless excision of the transgene from the genome seems to be the result. Expression of reprogramming factors from the transposon was controlled by a doxicyclin inducible promoter, hence allowing temporal control of factor transcription. We assume that this technique will prove extremely useful because the transposon-based system is applicable in a wide range of cells, and the possibility to excise the whole transposon by repeated transfection with transposase prevents the disadvantages of remaining exogenous pluripotency factor coding sequences or resistant marker genes in the nucleus.
Generation of iPS with less than four factors
Beside the establishment of techniques to circumvent introduction of reprogramming factors into the genome of the target cells, scientists are increasingly look-
Among the four "Yamanaka factors", c-myc has been thought to have the highest oncogenic potential. Reactivation of c-myc is the key event in the pathogenesis of Burkitt's lymphoma, and recent research pointed out a role of c-myc in a very broad range of malignant neoplasias and its association with poor prognosis [for review, see [61] ]. Likewise, reactivation of the retroviral-transduced c-myc in mice generated from 4-factor iPS cells was associated with high incidence of neck tumours. Histological examination of one tumour confirmed malignancy [45] . The three other factors were not associated with tumorigenesis. Thus, the highest efforts in the reduction of the numbers of factors needed for reprogramming currently concentrate on elimination of c-myc.
In contrast to c-myc, the role of Klf4 in carcinogenesis is ambiguous. It can act context-dependent as a tumor suppressor gene, especially in gastrointestinal tumors, or as oncogene, e.g. in the development of breast carcinoma where it is involved in the early phase of malignant transformation [62] . Reprogramming of human neonatal foreskin fibroblasts in the absence of c-myc and Klf4 became first possible with a second set of four factorsOct4, Sox2, Nanog and Lin28 [4] . This set has also been efficient in reprogramming strategies that avoid genome integration [63] .
The first reduction to three factors Oct4, Sox2 and Klf4 induced pluripotency in mouse and human fibroblasts [64, 65] and other somatic cell types [66] . In addition, the generation of iPS cells was possible with the combination of Oct4, Sox2 and c-myc in the absence of Klf4. It was concluded that Oct4 and Sox2 in combination with either c-myc or Klf4 were sufficient [66] . The price to pay, however, was a substantial decrease both in reprogramming efficiency and kinetics. Nakagawa and colleagues reported an estimated reprogramming efficiency of <0.001% [64] . Thus, more than 10 5 fibroblasts need to be infected to obtain one iPS colony. Slow and inefficient reprogramming could favour cells with genetic and epigenetic anomalities like culture adaptations, in this way counter-acting the reduced number of factors.
To further reduce the number of factors needed, and to maintain efficiency and kinetics of reprogramming at an acceptable level, several strategies have been shown to be successful.
The choice of the initial cell type has a great influence on reprogramming. Neural progenitor cells have a high endogeneous expression level of Sox2. In these cells, the first reprogramming without transduction of Sox2 could be shown using Oct4, Klf4 and c-myc [67] . Other studies also denoted the use of another set of factors including Sox2, Oct4 and the nuclear receptor Essrb, which could apparently replace Klf4 for reprogramming [68] .
A further reduction of factors in this cell type to two could be achieved by the combination of Oct4 with either Klf4 or c-myc. The latter was less efficient in the induction of pluripotency since it took 3-4 weeks to observe Oct4 expression, compared to 2-3 weeks with Klf4. However, the estimated reprogramming efficiency was ten times higher than in the original 4-factor approach in fibroblasts. Finally, reprogramming using only Oct4 in the absence of any other factor became possible in neural stem cells derived from adult mice [69] and humans [70] . Reprogramming of human neural stem cells, however, required mechanical manipulation since in the center of iPS colonies, a remainder in form of a 'neural rosette' was formed. Pure human IPS cultures could only be achieved by removing these cells manually.
Here, the authors reported an estimated reprogramming efficiency comparable to the initial 4-factor cocktail used on fibroblasts. However, the accessibility of neural progenitor cells in a clinical setting is -as a matter of course -not given. Melanocytes are like neural progenitor cells of neuroectodermal origin and express Sox2 endogeneously. This cell type is reported to be amenable to reprogramming in a comparable way, with the clear advantage of simple obtainability. Reprogramming with the original four "Yamanaka factors" was possible with a relatively high efficiency (0.05% in human melanocytes), and withdrawal of Sox2 decreased reprogramming efficiency to 0.01% [71] .Together, these studies indicated that Oct4 is crucial for reprogramming and may be difficult to replace by other factors. However, later studies showed that the nuclear receptor Nr5a2 could replace Oct4 in reprogramming MEFs [72] .
A second strategy is the substitution of single reprogramming factors by small molecules. The first effective substance which could substitute the task of c-myc or Klf4, was valproic acid (VPA), thus making reprogramming of human fibroblasts possible only by retroviral transduction of Oct4 and Sox2 [73] , with a 200-fold reduction of reprogramming efficiency compared to Oct4, Sox2 and Klf4 in combination with VPA. Among its extremely complex pharmacological profile, VPA acts as histone deacetylase inhibitor as indicated above. Based on previous reports of the use of histone deacetylase inhibitors in somatic cell nuclear transfer, the authors concluded that it might have a similar effect in reprogramming with defined factors, which turned out to be true [39] . Other authors utilized high-throughput assays to identify chemical factors which can substitute reprogramming genes. Thus, Klf4 could be chemically substituted by the application of kenpaullone [74] , and two other small molecules (BIX-01294 and Bayk8644) could enable reprogramming of embryonic fibroblasts with only Oct4 and Klf4 [75] . The same combination of factors could reprogram human keratinocytes in the presence of the glycogen synthase kinase-3 inhibitor CHIR99021 and the lysine specific demethylase I inhibitor tranylcypromine [76] . The authors of this study speculated that a switch to a complete chemically defined condition for reprogramming might be a desirable goal. It will be interesting to see how fast in the future this can be reached.
Enhancement of iPS production
Due to the low efficiency of iPS production, different factors have been investigated in order to improve this procedure. Diverse strategies have been used to enhance the induction process. Simultaneous transducion of c-myc, Oct4, Sox, Klf4, with Nanog and Lin28 increases yields dramatically, as described earlier [77] . Other studies have shown that lateral expression of p53 siRNA and UTF1 dramatically increases iPS colonies [43] . While p53 siRNA remarkably increases the number of iPS colonies, UTF1, a pluripotent marker and necessary for the maintenance of pluripotency in mES cells [33, 78] , raises the proportion of AP positive colonies. By affecting different pathways, these two factors together can synergize iPS generation [43] . Other studies have shown that UTF-1 promoter driven neomycin selection of iPS cell lines greatly refined iPS quality and increased their pluripotency characteristics such as AP and SSEA1 expression [47] . On the other hand, induction of iPS from fibroblasts and differentiated T cells with p53 deletion accelerated iPS production dramatically, indicating that p53 acts similarly in tumorigenicity and iPS production by suppressing both pathways. This deletion promotes inhibition of the p53-p21 pathway, leading to lower amounts of p21 protein levels. Additional data showed that p21 over expression notably inhibits iPS production [79] .
Other pathways which have an impact on iPS formation include the TGFβ and the MEK-ERK pathway. The role of these pathways in cell survival has made them beneficial in reprogramming studies. Chemical inhibitors of the MEK pathway apparently inhibit the growth of non-iPS cells while increasing the growth rate in reprogrammed iPS cells. This phenomenon is possibly due to the fact that somatic cells require MEK for cell cycle in contrast to mESC. This method can be used as a strong selection tool for reprogrammed iPS cells (A combined chemical and genetic approach for the generation of induced pluripotent stem cells [80, 81] .Accordingly, suppressing MEK and TGFβ pathways concurrently with chemical compounds increases iPS yields. This study showed that combined suppression of both pathways resulted in extensive amounts of iPS generation in comparison to individual inhibition of each pathway [80] .
Repression of the Ink4/Arf locus which is a regulator of the p53-p21 pathway has a positive effect on reprogramming. Silencing or deletion of the Ink4\Arf locus profoundly accelerated reprogramming in these experiments [82] .
Most pluripotency gene promoters like Nanog, Oct3/ 4 and FBX15 are highly methylated in pre iPS cells. Inhibition of DNA methyltransferases by 5-aza-cytidine (AZA) caused most pre-iPS cell lines to progress into a fully reprogrammed state. The effect of this inhibitor was also investigated on the overall reprogramming efficiency of MEFs to iPS cells. Studies indicated no overall increase in iPS efficiency when AZA was added at primary stages of induction. However, when AZA was added at day 8 into reprogramming, there was several fold increase in both iPS colony numbers and Oct4-GFP expressing colonies [83] .
Different pluripotency genes are controlled by the expression of different micro RNAs expressed in the cell. For example, let-7 is one of the miRNAs which targets the 3'UTR and ORF's of several pluripotency expressed genes including c-myc, Oct4, Sox2 and Nanog. Suppressing let-7 by antisense inhibitors improves iPS generation several fold in mouse embryonic fibroblasts (MEFs) [84] .
The microenvironment of a cell greatly determines its fate. It is known for some time, for example, that reduced oxygen levels favour the growth of haematopoietic stem cells and maintain ES cells in a pluripotent state. Induction of pluripotency in hypoxic conditions increases both the number of iPS colonies and alkaline positive colonies. Recent studies indicate that hypoxia also reduces the time required for iPS generation, showing increased Oct4-GFP positive colonies in a shorter period of time [85] .
An unpredicted factor which elevates iPS reprogramming efficiency is vitamin C, which has strong antioxidant properties [86] . Surprisingly, the increase in iPS formation is not due to its antioxidant activity. Seemingly, vitamin C inhibits p53, thus facilitating the induction of iPS cells [87] . These studies showed that vitamin C extends the life span of both iPS and MEF cells pointing at roles for vitamin C in anti-ageing.
Composition of the iPS culture medium also defines the efficiency of iPS formation. Studies showed that 20% knockout serum (KOSR) greatly improves induction compared to 15% Fetal Bovine Serum (FBS) that is used generally in iPS medium [88] . Replacement of FBS with KOSR generated Oct4-GFP colonies earlier and in higher numbers. Interestingly, AP+ colonies were doubled in KOSR containing medium when compared to FBS-containing medium. Colonies derived from KOSR medium appeared positive in both chimera formation and tetraploid complementation, demonstrating an exquisite degree of pluripotency [88] .
Using the above factors together with different chemical agents mentioned earlier can substantially enhance iPS induction. This may result in the derivation of more pluripotent cells in a shorter time, making its application more convenient for clinical purposes in the near future.
Similarities and differences between ES and iPS cells
The comparison of iPS and ES cells revealed that these cells are very similar in a variety of aspects. The differentiation capacity of iPS cells seems to resemble that of ES cells, and first reports suggest that iPS cell derived somatic cells are comparable to those derived from ES cells. Several studies describe the derivation of a variety of cell types from murine and human iPS cells, among them cardiomyocytes, smooth muscle cells, hepatic cells and neurons with similar differentiation behaviour of iPS and ES cells. Gene chip analysis has been utilized to assess the global transcriptome of iPS and ES cells and led to the conclusion that these cells are very similar -but they are not identical. In a systematic approach, Chin and colleagues compared the expression pattern of different human ES and iPS cells. Moreover, they analysed histone modifications and the expression of non-coding miRNAs in these groups and end up with a fingerprint of iPS cells that distinguishes them from embryo-derived pluripotent cells. It was described that the expression pattern of iPS cells changes during culture and adapts to ES cells. This finding might reflect ongoing mechanisms of reprogramming in these cells. However, comparison of the transcriptome of early and late passage iPS cells of human origin with ES cells revealed two datasets of differentially regulated genes. Comparison of all expression patterns identified a subset of 318 genes differentially expressed between human ES and iPS cells at any stage. Intriguingly, those genes that are higher expressed in iPS cells were also found higher expressed in fibroblasts than in ES cells in most cases. On the other hand, genes that were expressed at a lower level in iPS than ES cells are usually also lower expressed in fibroblasts than ES cells. Together, these findings point at an imperfect reprogramming of a small set of genes that somehow represents a "genetic memory" of a cell's ancestor. In this regard, we have to differentiate between genes that make the potential iPS fingerprint of all iPS cells and genes that make up the genetic memory of individual cell lines. Currently, it is not known if there are implications of iPS fingerprint for the physiology of these cells. The analysis of genes that are differentially regulated and might influence the cellular physiology is not trivial. It is likely that some of these gene functions are redundant with others that are not affected by incomplete reprogramming and, therefore, do not influence cell physiology. Furthermore, the developmental function of many genes involved here is currently not known. For example, expression of BAMBI (bone morphogenic protein (BMP) and activin membrane-bound inhibitor) is found largely reduced in human iPS cells compared to human ES cells [89] . The known function of BAMBI is the antagonization of transforming growth factor beta (TGFβ)/BMP/activin signalling with a general suppressive effect on these signalling pathways. It can be speculated that the differential expression of BAMBI may influence maintainance of pluripotency and differentiation in the iPS cell lines. However, a knock out of BAMBI by elimination of the first exon in mice did not reveal any phenotype in -/-animals, leaving the physiological role of this pseudo-receptor elusive [90] . On the other hand, it was shown that knock down of BAMBI in a human ES system leads to increased TGFβ signalling [91] and that BAMBI influences the Wnt/ beta-catenin signalling pathway in a positive manner [92] . Interestingly, it was reported that the cyclic activation of the Wnt/beta-catenin signalling pathway results in a substantial increase of ES cells to reprogram somatic cells after fusion [93] . This correlation agrees with the finding that BAMBI is higher expressed in iPS than ES cells, but does not necessarily imply that it is of physiological relevance. Overlay of differentially regulated genes in human ES and iPS with differentially regulated genes in murine ES and iPS cells might reveal a universal fingerprint of iPS cells. A comparative study has produced a list of genes that are supposed to be differentially regulated in human as well as murine iPS when compared to ES cells. These genes, BAMBI is not among them, span a wide range of different functions [89] . Whether these genes really distinguish any iPS cell from blastocyst-derived cells will hopefully be revealed in the future. In any case, it is remarkable that the differences in gene expression are after all very small and often restricted to only a few hundred.
Beside genes that constitute a potential iPS cell fingerprint, there are varying gene sets that are differentially expressed in individual iPS cell lines. How these cell line specific variations affect cell function is not elucidated at the moment, but it is likely that cell line specific modifications in the expression profile affect cellular physiology in a notably dimension (Pfannkuche and colleagues, unpublished data). It will be interesting to see if properties of the ancestral cell types are transmitted to the iPS cell line generated. In this regard, partial reprogramming plays a role and one fascinating aspect to address is if partial reprogramming alters the differentiation capacity of a cell in a way that it potentially influences the fate decision of the partially reprogrammed iPS cells. One of the many open questions remaining is if somatic cells can be directly reprogrammed to different types of somatic cells without generation of pluripotent intermediates. Indeed, Vierbuchen and colleagues recently reported a strategy to transform fibroblasts to neuronal cells by direct delivery of only three factors: Ascl1, Brn2 and Myt1l [94] . In addition, Melton and co-workers showed that they can tweak exocrine pancreatic into endocrine cells in vivo [95] .
Another important issue is the question whether the maternal and paternal imprinted genes keep their monoallelic expression during the process of reprogramming. Imprinted genes express only the maternal or paternal allele, whereas the second allele is silenced. It is known that human ES cells tend to aberrant expression of imprinted genes with high passage numbers but generally maintain their imprinting pattern [96] [97] [98] . The analysis of single nucleotide polymorphisms allows to distinguish between expression of both alleles and therefore to identify mono-or biallelic expression of imprinted genes. Analysis of the imprinting pattern in human iPS cells revealed that most of the iPS lines analysed show monoallelic expression of the imprinted genes, thus demonstrating that the fibroblasts used for reprogrammingeven if they do not express some of the imprinted genes at all -are able to forward the imprinting information properly [99] . Besides the finding that monoallelic expression of imprinted genes is usually maintained in human iPS cells, Pick and colleagues identified iPS cell lines with aberrant biallelic expression of some imprinted genes, and it is worth noting that some genes are more prone to pertubation of expression than others. These data point to the importance to analyse the expression of imprinted genes in iPS cell lines that are determined for therapeutic use, because disturbed expression of imprinting patterns can give rise to genetic disorders. The differences between iPS and ES cells might be subtle and assays to measure the quality of iPS cells are still not fully evolved. Highly stringent assays for pluripotency, like germ line transmission in chimaeric animals and the tetraploid complementation assay can be employed for murine cells, but are not applicable to human iPS cells for obvious reasons [100] . A recent report by Han and colleagues indentifies the t-box transcription factor Tbx3 as a strong enhancer of germline potency of iPS cells [101] . Reprogrammed cells that were generated in the presence of Tbx3 resulted in a substantial increase in germline transmission of the iPS cells in chimaeric animals, when compared with iPS cells that were generated under the same conditions but in the absence of Tbx3. A comparison of the transcriptome of both types of iPS cells did not reveal obvious differences. This finding indicates that transcriptome analysis of iPS cells in comparison to ES cells is not sufficient to evaluate the quality of iPS cells. Detailed analysis of differentiating iPS cells will uncover further potential differences between ES and iPS cells.
Although it has been shown that the overall gene expression of iPS cells differs from normal ES cells, this comparison has never been made between cells from the same individual. Usually iPS cells are compared with those ES cells either derived from another species or from a different individual; raising concerns about whether these are informative approaches. It is clear, therefore, that iPS cells derived from the trophoblast of an embryo compared with ES cells derived from the inner cell mass of the same embryo would give a more explicit view of how distinct or similar these cells really are.
Applications for clinical models in cardiovascular biology and medicine
With the development of the reprogramming techniques, it has become possible to generate patient-tailored iPS cell lines from donors independent of sex or age. This possibility has major implications for several fields of research. With the possibility to generate pluripotent cells perfectly matching the donors genetic background, it is now possible to generate a variety of somatic cells that are immunological identical to the donor tissue and therefore are not rejected by the immune system. In addition, no human ES cells are used at any stage of the process eliminating ethical concerns. One important implication of this development is a political: The use of adult stem cells from different tissues and many from the bone marrow has been supported and granted by several institutions with the background that these cells are ethically unproblematic and can be easily derived from every patient matching its immunological parameters. The discovery of iPS cells might challenge the advantages of the adult stem cells as a tool for cellular replacement strategies in some areas because of the unrestricted expansion and differentiation potential. It is, of course, likely that adult stem cells still hold a capacity for applications in a variety of treatments, but the advantages of iPS cells over ES cells will prompt to reconsider the focus of granting primarily adult stem cells research in some areas.
With the iPS cell technology it has become possible to isolate somatic cells, generate pluripotent iPS cells, and genetically engineer these cells for different purposes. The unique performance of this strategy was demonstrated by the group of Rudolf Jaenisch who could show for the first time that iPS cells are capable to cure genetic diseases under some circumstances: A murine model of sickle cell anaemia was used to isolate fibroblast cells. The cells were expanded in culture, genetically engineered, and applied to repair the defect in the hemoglobin gene that accounts for sickle cell anaemia [102] . The modified cells were reprogrammed to iPS cells and subsequently differentiated to hematopoetic progenitors in vitro. The progenitor cells were transplanted into donor mice and gave rise to functional erythrocytes not showing any signs of sickle cell anaemia. This report demonstrated impressively the feasibility to treat a genetic disease with iPS cell based techniques. Even though it is exciting to see these novel perspectives, it will be much more complicated to repair cells of other origins than bone marrow because the exchange of damaged, untreated cells for repaired cells is much more complicated or even impossible in many cases. Another interesting feature of patient tailored iPS cells is the possibility to generate disease model-specific iPS cells. For many genetic diseases, the physiology of pathogenesis is not completely known and, especially for rare diseases, development and testing of pharmacological agents to treat the disease appears difficult. In this respect, the generation of iPS cells from different donors with genetically caused diseases might allow to recapitulate the onset of the patho-physiological changes directly in vitro and to understand the molecular details.
Cardiac differentiation of murine iPS cells
The principal capability of cardiac differentiation was independently shown by three research groups using either a directed differentiation approach or the traditional hanging drop method [103] . The directed differentiation approach was based on the identification of Flk1 + -progenitors purified by cell sorting [104, 105] . Derived from ES cells, Flk1 mural cells and, finally, cardiomyocytes; thus with the exception of fibroblasts, most of the mesodermal cell types forming the cardiovascular system can be derived from this cell population. Differentiation to cardiomyocytes of these cells can be induced by culture on OP9 stromal cells or an extracellular matrix consisting of collagen IV. In both publications, no differences in the time course of Flk expression and cardiac differentiation could be found between iPS and ES cells. However, the Flk expression at different time points was twice as high in the report by Schenke-Layland et al. [105] compared to Narazaki et al. [104] In contrast, Mauritz et al. [103] observed a delay in the appearance of beating areas and a lower expression of troponin T in iPS cells differentiated in hanging drops compared to ES cells [103] . This finding was confirmed by two other publications [106, 107] .
The electrophysiological properties can be examined at different levels of functional organization, including isolated single cardiomyocytes [104] [105] [106] and beating areas integrated in embryoid bodies [103, 107] .On the single cell level, biophysical properties of expressed ion channels in two different iPS cell lines were comparable to those in embryonic stem cell derived cardiomyocytes (ESCMs) and native fetal cardiomyocytes at equivalent developmental stages [106] . Current densities of L-type calcium channels varied strongly among different cell lines. In contrast, sodium channels and potassium channels were similar. Atrial-and ventricular-like action potentials could be observed as reported earlier for ESCMs [108] . Blockers of sodium, L-type calcium and the rapidly-activating delayed recifier currents as well as adrenergic and muscarinergic regulation revealed a physiological behaviour as expected for native cardiomyocytes. An increase in current densities and a decrease in action potential duration had been described in later stages of differentiation as it would be expected regarding the normal development.
On the level of beating areas integrated in embryoid bodies, the pharmacological effects were comparable to the single cell level [107] . Interestingly, the action potential duration on this level correlated highly with the beating frequency. This finding suggests a high homogeneity in the mechanisms involved in repolarization; this is contradictory to the finding of different cardiac subtypes at the single cell level. Moreover, the action potential shape and the beating frequency in this study were highly different between iPSCMs and ESCMs. So far it is not clear whether this reflects principle differences between iPS and ES cells, or whether this phenomenon can also be observed by comparing different ES cell lines.
Cardiac differentiation of human iPS cells
The expression of cardiac markers in differentiating iPS cells including Nkx2.5 and a number of proteins related to the cardiac contractile apparatus was already observed by Takahasi et al. [109] . These observations were more recently confirmed and expanded. Zwi et al. reported a strong up-regulation of calcium channel, potassium channel and funny channel transcripts [110] , Zhang and colleagues furthermore found an upregulation of phospholamban and the atrial natriuretic factor [111] . The coexistence of iPSCMs with sinoatrial, atrial and ventricular cardiomyocytes, the rate adaptation of the action potential duration and the effects of adrenergic and muscarinergic drugs could be demonstrated for iPS cells [111] in exactly the same manner as for ES cells [112] . The effects of cardioactive drugs on field potential parameters and conduction velocities of ESCMs [113] have also been reproduced for iPSCMs [110] . Thus, there is strong evidence that human iPSCMs and ESCMs are to a high degree functionally comparable.
Accounting for murine and for human cells, within a short time a number of studies confirmed that functional iPSCMs can be generated, which share many properties of native cardiomyocytes.
IPSCMs as an in vitro model for testing cardioactive drugs
In general, the safety evaluation of biological agents is further complicated by the fact that they are designed to act on a human target. Traditionally, widely used animal models might therefore be a less relevant choice. To detect potential safety issues associated with this class of drugs, human cell models must be developed that detect parameters such as cell viability and force of contraction. Pluripotent stem cell lines, either ESC or iPS cells, are therefore considered promising novel tools for drug testing in part because they may be derived as healthy controls, but also because of the opportunities they represent for creating cardiac disease models. One of the major concerns in drug development is the induction of ventricular arrhythmias and sudden cardiac death, which correlates with the prolongation of the QT duration in the electrocardiogram. The early identification of substances, in which this effect is greater than the expected therapeutical benefit, is crucial in order to make the development of drugs cost-effective. On the cellular level, one of the most studied mechanisms of QT prolongation is block of the HERG channel and, on the level of the ventricular wall, the transmural dispersion of repolarization leads to QT prolongation which is strongly associate with induction of arrhythmias.
Human pluripotent stem cell-derived cardiomyocytes could potentially ameliorate the early detection of this property. Their human origin, the dispensability of animal consumption and the high costs of the current screening methods are major constituents of the list of pro-arguments. After application of QT prolonging drugs, human ESCMs [113, 114] and human iPSCMs [110, 115] , showed an increase of the extracellular field potential duration [116] . The workflow is extremely easy: ES or iPS cells are differentiated, beating areas are selected and plated on multielectrode arrays. The drug of interest is applied, and the signals before and after drug application are compared.
It should be kept in mind that -if this approach is hoped to have the potential of a sufficiently high specificity and selectivity -it is based on a chain of assumptions which are by no means obvious. 1) The mechanisms in the prolongation of the action potential of iPSCMs should reflect those in the adult myocardium. Due to the paucity of data on ion channel constitution of ES-and iPSCMs of human origin, it is impossible to predict the mechanisms underlying the increase of action potential duration. It is likely, that with the present methods of differentiation, iPSCMs remain immature [117] . Moreover, due to the lack of effective purification methods, the tissue environment is subjected to a high degree of variability and may confound drug effects. Thus, it is not clear whether the mechanisms of action potential duration regulation are comparable to cardiomyocytes in human myocardium.
2) The mechanisms of the field potential prolongation in multielectrode arrays should reflect those underlying the QT prolongation in the electrocardiogram. 3) Although QT prolongation is clearly associated with a higher incidence of ventricular arrhythmias, there is a number of important drugs prolonging the interval by mechanisms being not pro-arrhythmogenic, e.g. the antiarrhythmic drug amiodarone [118] . Given these considerations, it is clear that the use of iPSCMs as a basis for drug testing is, at the same time, a highly complex, but also highly attractive aim.
iPSCMs as disease models
Induced pluripotent stem cells can be derived from patients with complex genetic defects to create disease models. Clinically relevant mutations can be derived from cells of patients with a particular genetic disease of choice. This should facilitate the creation of innovative human disease models caused by simple as well as complex genetic abnormalities. IPS cell lines can be generated without integration of transgenes, as required in the original method [59, 63] . Although there is accumulating evidence that iPS cells differ from ESCs based on analysis of methylation state and gene (mRNA) and miRNA expression, it seems most likely that the cells can be used to study disease processes.
Some disease-associated mutations might interfere with iPS cell generation as shown for mutations in the Fanconi Anaemia pathway [119] . Nevertheless, several of these disease-specific iPS cells have been generated for haematological [102, [119] [120] [121] and neurological diseases [122] [123] [124] , which reflect the disease phenotype. Hence iPS cells represent an opportunity to study disease development in vitro and can therefore serve as a powerful disease model.
It is highly probable -although so far not demonstrated -that iPS cells can also be generated from patients suffering from genetic heart diseases. Thus, the major question is, what do we need them for? Reformulated more precisely: What are the limitations of current disease models which could be surpassed by diseasespecific iPS cells?
Our knowledge on inherited disorders of heart rhythm -e.g. long QT syndrome, short QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia -is mainly based on the iterative process between observation of patients and disease models. Many mouse models have been generated for these diseases and have provided great insight into the underlying mechanisms. Their major limitation are the enormous differences in the electrophysiological properties between human and murine cardiac myocytes [for review, see [125] ]. Species which resemble the human cardiac electrophysiology like dog or guinea pig in contrast are not easily amenable to genetic manipulation. They were nonetheless extremely useful in exploring this mechanisms by pharmacological simulation of mutant ion channels mainly in the arterially perfused wedge preparation [126] . Finally, expression systems like Xenopus oocytes revealed important biophysical properties of identified mutations in ion channels without giving information of the cellular and tissue context.
Human disease-specific iPS cells might be able to fill in these gaps carrying the genetic alterations in the 'native' cellular context. To achieve this goal, one of the major challenges will be to lead iPSCMs to mature phenotypes.
iPSCMs for therapy
Transplantation of pluripotent stem cell-derived cardiomyocytes could restore function of failing hearts by replacing damaged cardiomyocytes. Transplanted cells would have to be immunomatched, integrate into the host myocardium, and receive a blood supply. Furthermore cardiomyocytes should couple with residual host cardiomyocytes to contract. Proof-of-concept has been demonstrated in animal experiments using neonatal or embryonic cardiomyocytes. Generation of force and transfer of force have been shown for murine [127, 128] and human embryonic stem cell-derived cardiomyocytes [129] in an in vitro-model of simulated ischemic injury. Additional in vivo-studies have shown that embryonic stem cell-derived cardiomyocytes can enhance cardiac function after transplantation [127, 130] , most likely because of an active contribution to the contraction force of the heart. However, functional improvement of hearts with hESC-derived cardiomyocytes was observed at 4 weeks [130, 131] , surprisingly, despite graft survival even up beyond 6 months, functional improvement was not sustained at 12 weeks [132] . Van Laake et al. showed that transplanted hESC-derived cardiomyocytes formed intercellular contacts with each other, but were usually separated from the surrounding host mouse myocardium by a thin layer of extracellular matrix so that functional coupling may not have taken place [132] . In addition, it remains unclear whether human cardiomyocytes could keep pace with the much higher rate of rodents. Overall, functional enhancement by hESC-CM with the current strategies seems to be limited to mid-term at most [133] .
A big advantage of iPS cell-derived cardiomyocytes will be the possibility to generate isogenic cardiomyocytes, which are genetically equivalent to the cells of the transplant recipient.
The beneficial effects of ESCM transplantation in a mouse model of myocardial infarction [127] could be reproduced for iPSCMs so far in one study [134] .
Using two different approaches to simulate myocardial infarcation -ligation of the left coronary artery in the study by Nelson et al. and cryo-infarction in the study by Kolossov et al. -similar values of the left ventricular ejection fraction after myocardial infarction and subsequent cell transplantation were obtained indicating a strong benefit two weeks after transplantation. A slight decrease of the ejection fraction was observed another two weeks later. However, whether this is a result of cell loss remains to be seen.
iPSCMs provide also the opportunity to assess the risk of tumor/teratoma formation. Most interestingly, Nelson et al. [134] did not observe tumor formation in immunocompetent mice, although they did not purify the cardiomyocyte fraction. This is in clear contrast to the Kolossov study [127] , which pointed out that the purification of cardiomyocytes is essential to prevent tumor formation. While arrhythmias were not observed in the Nelson study, they noted an increase of the QT duration after infarction, which was partially reversible by trans-plantation of iPSCMs. This is also in contrast to an earlier study [135] , which did neither observe an effect of the infarction nor of the transplantation of embryonic cardiomyocytes on the QT duration. Since heart rhythm was stable as well in the control animals, a direct antiarrhythmic effect could not be observed.
Taken together, the clinical use of cardiovascular derivatives from pluripotent stem cells would appear challenging because successful functional integration into the host myocardium is still not achieved. Safety issues are going to be a major hurdle. Furthermore, an individualized therapy with IPSCMs would be very costly and the time taken to derive and characterize iPS cells from one patient too long to treat anything but chronic ailments [136] .
iPS cells of non-human mammals
ES cells could be derived from a number of nonhuman species, including mice [137, 138] , dog [139] and non-human primates [140] . However -with the exception of mice and humans -the literature on cardiac differentiation and application in cardiovascular research is extremely scarce. Rhesus monkey ES cells have been differentiated to ESCMs [141] ; subsequent reports on applications are nonetheless outstanding. Missing ES cells from pig, rat, guinea pig fulfilling the complete catalogue of pluripotency criteria, several of the most widely used animal models in cardiovascular medicine do not have equivalent in ES cells. Thus, transplantation experiments in this species have been conducted par force as xenotransplantation, typically transplanting human ES cells or ESCMs into rats [142, 143] , guinea pigs [144] or pigs [145] .
In contrast, the iPS principle seems to be readily applicable to some of these species. So far, the successful generation of porcine [146] [147] [148] , rat [149, 150] , canine [151] , and rhesus monkey [152] iPS cells have been reported. The cardiac differentiation of these cell lines has not been investigated, only the expression of early cardiac markers has been observed by Liu et al. [152] . Thus, it remains to be speculated that iPS cell technology might hold the potential to revolutionize also the area of transplantation models, enabling allo-or autologous transplantation of iPS cells and their derivatives in large animals and in animal models with high impact in cardiovascular research, which is a major prerequisite for the assessment of feasibility and safety of cell transplantation. 1 
